Switzerland's Nitec Pharma, a specialist pharmaceutical company focused on the treatment of chronic inflammatory diseases, says that it has granted German marketing rights to Merck Pharma GmbH for the rheumatoid arthritis drug Lodotra, its modified-release tablet designed to optimize the efficacy of orally-administered low-dose prednisone. The product was originally developed by Merck, in collaboration with UK-based drug developer SkyePharma, before Nitec was spun-out as a separate entity in 2004 (Marketletters passim). Merck retained the option to market the drug in its home territory, and decided to exercise this right after the product achieved positive results in a Phase III trial. Financial terms of the deal were not provided.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze